- Home
- PRVA vs APGE Comparison
PRVA vs APGE Comparison
Compare PRVA & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRVA | APGE |
|---|---|---|
| Founded | 2007 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 4.7B |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | PRVA | APGE |
|---|---|---|
| Price | $19.95 | $79.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | $31.00 | ★ $109.25 |
| AVG Volume (30 Days) | 782.7K | ★ 1.0M |
| Earning Date | 05-07-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.64 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $2,122,842,000.00 | N/A |
| Revenue This Year | $14.66 | N/A |
| Revenue Next Year | $10.48 | N/A |
| P/E Ratio | $112.06 | ★ N/A |
| Revenue Growth | ★ 22.26 | N/A |
| 52 Week Low | $18.78 | $26.20 |
| 52 Week High | $26.51 | $85.04 |
Technical Indicators
Market Signals| Indicator | PRVA | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 32.22 | 60.14 |
| Support Level | $19.54 | $73.06 |
| Resistance Level | $24.13 | $81.04 |
| Average True Range (ATR) | 0.64 | 4.62 |
| MACD | -0.23 | 0.96 |
| Stochastic Oscillator | 12.73 | 73.26 |
Price Performance
Historical ComparisonAbout PRVA Privia Health Group Inc.
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.